Landmark BMJ Meta-Analysis Finds Calcium and Vitamin D Supplements Do Not Prevent Fractures in Most Adults
A comprehensive systematic review and meta-analysis published in The BMJ in 2024 examined 81 randomized controlled trials involving over 100,000 participants and concluded that calcium, vitamin D, or combined supplementation has little to no meaningful effect on preventing fractures and falls in the general adult population. This finding challenges decades of clinical guidance recommending these supplements for bone health. The analysis pooled data from trials published through 2023, representing one of the most comprehensive assessments to date of whether supplementation actually reduces fracture risk in community-dwelling adults.
What Happened
Researchers conducted a systematic review and meta-analysis synthesizing evidence from 81 randomized controlled trials to evaluate the efficacy of calcium, vitamin D, and combined supplementation in preventing fractures and falls. The analysis examined trials published up to 2023 across multiple databases and included participants of various ages and risk profiles. The team pooled data on fracture incidence, fall risk, and bone mineral density outcomes across the included studies to generate summary effect estimates.
According to The BMJ publication, the meta-analysis found that calcium supplementation alone showed minimal benefit for fracture prevention in community-dwelling older adults. Vitamin D supplementation also demonstrated little to no effect on hip, vertebral, or non-vertebral fractures when used as a standalone intervention. Even when calcium and vitamin D were combined—a strategy long recommended by major health organizations—the protective effect on fracture risk remained negligible in most subgroups examined.
What the Research Says
The BMJ meta-analysis pooled data from 81 randomized trials with a combined sample exceeding 100,000 participants. The analysis evaluated multiple primary outcomes: hip fractures, vertebral fractures, non-vertebral fractures, and falls. Most trials included community-dwelling adults aged 50 and older, though some examined younger populations and those with existing bone disease.
For calcium supplementation alone, the relative risk reduction for hip fractures was approximately 1.02 (95% confidence interval 0.97–1.08), indicating no meaningful protective effect. Vitamin D supplementation showed similarly negligible results, with relative risk estimates hovering near 1.0 across fracture outcomes. When trials combined both supplements at typical doses—calcium 500–1200 mg daily and vitamin D 400–2000 IU daily—effect sizes remained small and often not statistically significant.
Notably, the analysis also examined bone mineral density as a surrogate outcome. While both calcium and vitamin D showed modest improvements in bone density at the spine and hip, these gains did not translate into clinically meaningful reductions in actual fracture incidence. The authors noted that the disconnect between improved bone density and unchanged fracture risk suggests that bone density alone may be an insufficient predictor of skeletal protection in supplemented populations.
Beyond the Headlines
This finding emerges from decades of clinical practice built on earlier observational research suggesting that calcium and vitamin D deficiency contributed to osteoporosis and fracture risk. Major health organizations, including the American Academy of Orthopedic Surgeons and the National Institutes of Health, have historically recommended supplementation, especially for postmenopausal women and older adults. The global supplement market for bone health products exceeds $2 billion annually, reflecting widespread uptake of these recommendations.
However, evidence from randomized trials has gradually accumulated showing more modest benefits than early observational studies suggested. The findings reflect a broader shift in clinical epidemiology toward prioritizing randomized controlled trial evidence over observational associations. Earlier cross-sectional studies showed that people with higher calcium intake had stronger bones, but RCTs randomizing individuals to supplementation have consistently shown smaller effects—a pattern suggesting that confounding factors such as overall health, physical activity, and nutritional status may have inflated the apparent benefits in observational work.
The analysis does identify potential exceptions: individuals with very low baseline vitamin D status or those living in residential care facilities showed modest benefits from supplementation, suggesting that benefit may be population-specific rather than universal. This nuance is critical for interpreting the headline finding.
What This Means for Consumers
For most adults in the general population—particularly those without diagnosed osteoporosis, vitamin D deficiency, or fracture risk factors—the evidence does not support routine calcium or vitamin D supplementation for fracture prevention. If you are considering starting a calcium or vitamin D supplement specifically to prevent broken bones, ask your healthcare provider whether you fall into a higher-risk group (such as those with documented osteoporosis, severe vitamin D deficiency confirmed by blood testing showing 25-hydroxyvitamin D below 20 ng/mL, or history of fragility fractures) where evidence suggests more targeted benefit.
Individuals already taking these supplements need not stop abruptly, as the analysis does not show harm—only lack of substantial benefit for fracture prevention. However, the findings suggest that supplementation alone is unlikely to be a primary strategy for bone protection. Instead, evidence consistently supports weight-bearing exercise (such as walking or strength training), adequate protein intake (1.0–1.2 g per kilogram of body weight daily), and muscle-strengthening activities as effective approaches to maintaining bone health and reducing fall risk.
For those concerned about bone density, request a DEXA scan and work with your provider to assess your actual fracture risk using validated prediction tools such as FRAX rather than assuming supplements will offset that risk. Dietary sources of calcium (dairy, leafy greens, fortified plant milks) and sun exposure for vitamin D synthesis remain reasonable first-line approaches for meeting micronutrient needs without relying on supplements.
What to Watch Next
The BMJ meta-analysis is likely to prompt guideline updates from organizations such as the American Academy of Orthopedic Surgeons, the Endocrine Society, and the American Geriatrics Society. Professional bodies may revise recommendations to reflect the limited evidence for universal supplementation, potentially narrowing recommendations to higher-risk populations. Regulatory agencies in various countries may also reassess marketing claims on supplement labels that emphasize fracture prevention without adequate evidence.
Ongoing trials examining vitamin D supplementation in specific populations—such as those with prior fractures or in very elderly cohorts—will continue to provide data. Additionally, researchers are investigating whether genetic factors, baseline micronutrient status, or concurrent medications may identify subgroups who do benefit from supplementation, potentially explaining the heterogeneity observed across trials. The next major milestone will be whether major public health agencies incorporate these findings into their official bone health guidelines by 2025–2026.